ブラジルの製薬市場展望2018

◆英語タイトル:Brazil Pharmaceutical Market Outlook 2018
◆商品コード:RNCOS41202
◆発行会社(リサーチ会社):RNCOS
◆発行日:2014年12月
◆ページ数:90
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:ブラジル
◆販売価格オプション(消費税別)
Single UserUSD1,000 ⇒換算¥104,000見積依頼/購入/質問フォーム
Multi-User(全社内共有可)USD1,400 ⇒換算¥145,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
RNCOS社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Brazil is considered as one of the most lucrative healthcare markets, accounting for the highest healthcare expenditure in Latin America. It is the largest pharmaceutical market in Latin America and the fifth largest globally. Strong government support and high healthcare services demand are two of the major factors propelling the country’s pharmaceutical market. Drug makers are also keen to tap the Brazilian market because it is one of the most lucrative and fastest-growing pharma markets worldwide. Pharma companies such as Sanofi, Pfizer, Boehringer Ingelheim, Sun Pharma, GSK, etc., have been trying to expand their businesses in Latin America following acquisition of domestic manufactures.

The Brazilian Government has adopted several initiatives and implemented appropriate plans and policies that have resulted in the positive development of the country’s overall healthcare services and facilities. In our latest research study “Brazil Pharmaceutical Market Outlook 2018”, RNCOS’ analysts have identified the market dynamics of major pharmaceutical segments such as Generics, OTC and Prescription Drugs. Accordingly, a study has been conducted for their current market sizes and forecasts for the next five years. The Pharmaceutical market, which stood at US$ 26.89 Billion in 2013, is expected to grow at a CAGR of 14.5% during 2013-2018.

RNCOS’ analysis shows that the Over-the-Counter drug and Generic drug segments have been the fastest growing and are expected to surpass the branded medications market in the near future. Government support to encourage the domestic drug industry, rising healthcare expenditure, patent expiry, reduced taxations, high disposable incomes, etc., are few important drivers resulting in high growth in these segments. Further analysis includes current market statistics, key drivers stimulating each segment’s growth, and future outlook of the segments.

EMS Pharma, Hypermarcas, Ache Laboratories, Eurofarma are the top four domestic pharma companies, with EMS Pharma and Ache Laboratories leading the Generics and Prescription Drug segments respectively. These companies contributed around 50% of the domestic pharmaceutical market in 2013. Among the foreign players, Sanofi, Novartis and Roche have been generating a significant amount of revenue from the Brazilian market since the last three years.

The report, covers all the necessary aspects of the Brazilian Pharmaceutical market, providing an in-depth research and prudent analysis of the key segments. The topics covered in the report include: Pharmaceutical Production, Prescription Segment, OTC Segment, Therapeutic Segment as well as Mergers and Acquisitions. The report also presents an insight into the current industry trends, key market drivers, and government initiatives to enable the clients understand the market structure and its growth during the forecasted period. The report also covers detailed information about active market players in the Brazil pharmaceutical industry, including domestic and foreign players.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Market Drivers
3.1 Public and Private Expenditure on Healthcare
3.2 Rising Number of Clinical Trials
3.3 Rising Disposable Income
3.4 Ageing Population
4. Market Challenges
4.1 High Prices of Medications
4.2 Dependence on Imported Drugs
4.3 Stringent Drug Licensing and Regulatory Laws
4.4 High Tax Burden
5. Pharmaceutical Industry Overview
6. Market Segmentation
6.1 OTC Drug
6.1.1 Regulatory Framework
6.2 Generics
6.2.1 Regulatory Framework
6.3 Prescription Drug
6.3.1 Regulatory Framework
7. Therapeutic Segments in Brazil
7.1 Oncology
7.2 Infectious Diseases
7.3 Cardiovascular and Diabetes
7.4 CNS Diseases
8. Mergers and Acquisitions (Premium Deals since 2010)
9. Competitive Landscape
9.1 Share of Domestic Vs International Players
9.2 Overall Market Share Breakdown
10. Key Players
10.1 EMS
10.2 Hypermarcas
10.3 Ache Laboratories
10.4 Eurofarma
10.5 Sanofi-Aventis
10.6 F. Hoffmann La Roche
10.7 Novartis
10.8 Pfizer
10.9 Merck Group

List of Figures:

Figure 3-1: Expenditure on Health (% of GDP), 2008-2013
Figure 3-2: Total Expenditure on Health per capita (PPP int.US$), 2008-2013
Figure 3-3: Share of Government and Private Expenditure (2012)
Figure 3-4: Government Expenditure on Health (% of total expenditure), 2008-2012
Figure 3-5: Private Expenditure on Health (% of total expenditure), 2008-2012
Figure 3-6: Number of Clinical Trials (2008-2014)
Figure 3-7: Annual Disposable Income (Million US$), 2010-2014
Figure 3-8: Disposable Income Brackets (%), 2012
Figure 3-9: Population above 65 Years (Million), 2008-2013
Figure 5-1: Share of Brazilian Pharmaceutical Market in Latin America (2013)
Figure 5-2: Pharmaceutical Production (Million US$), 2011-2013
Figure 5-3: Pharmaceutical Production Share by Use (2013)
Figure 5-4: Pharmaceutical Production by Use (Million US$), 2012 & 2013
Figure 5-5: Pharmaceutical Production by Ingredients (Million US$), 2012 & 2013
Figure 5-6: Pharmaceutical Production Share by Ingredients (2013)
Figure 5-7: Pharmaceutical Trade (Million US$), 2011-2013
Figure 5-8: Pharmaceutical Market (Billion US$), 2013-2018
Figure 5-9: Pharmaceutical Sales Volume (Billion Units), 2008-2013
Figure 6-1: Pharmaceutical Market Share by Segments (2013)
Figure 6-2: Pharmaceutical Market Share by Segments (2018)
Figure 6-3: OTC Drugs Market (Billion US$), 2013-2018
Figure 6-4: OTC Market Segmentation by Category (2013)
Figure 6-5: Generics Market (Billion US$), 2013-2018
Figure 6-6: Generics Drug Sales by Volume (Million Units), 2008-2013
Figure 6-7: Generics Drug Laboratories (2010-2013)
Figure 6-8: Generics Drug Market by Country of Origin (%), 2013
Figure 6-9: Number of Generics Drugs Registered by Company (2013)
Figure 6-10: Prescription Drugs Market Segmentation (2013)
Figure 6-11: Prescription Drugs Market (Billion US$), 2013-2018
Figure 7-1: Number of HIV Cases Registered (’000), 2005 & 2013
Figure 7-2: HIV Infection Rate in Adult Population (%), 2013 & 2030
Figure 7-3: Diabetic Patients in Age Group 20-79 Years (Million), 2013 & 2030
Figure 9-1: Share of Domestic and International Players (2013)
Figure 9-2: Market Share of Leading Players in Brazilian Pharmaceutical Market (2013)
Figure 10-1: Hypermarcas – Revenue Share by Business Segments (2013)
Figure 10-2: Ache Laboratories – Revenue Share by Business Segments (2013)
Figure 10-3: Sanofi-Aventis – Revenue by Business Segments (Million US$), 2012 & 2013
Figure 10-4: Sanofi-Aventis – Revenue Share by Geographical Regions (2013)
Figure 10-5: Sanofi-Aventis – Revenue Share by Different Regions in Emerging Market (2013)
Figure 10-6: Roche – Revenue Share by Business Segments (2013)
Figure 10-7: Roche – Revenue Share by Therapeutic Segments (2013)
Figure 10-8: Roche – Pharmaceutical Revenue Share by Geographical Regions (2013)
Figure 10-9: Novartis – Revenue Share by Business Segments (2013)
Figure 10-10: Novartis – Pharmaceutical Revenue Share by Geographical Regions (2013)
Figure 10-11: Pfizer – Revenue Share by Business Segments (2013)
Figure 10-12: Pfizer – Revenue Share by Geographical Regions (2013)
Figure 10-13: Merck Group – Revenue Share of Biopharmaceuticals by Geographic Regions (2013)
Figure 10-14: Merck Group – Revenue Share of OTC by Geographic Regions (2013)

List of Tables:

Table 3-1: Household Disposable Income Brackets (‘000), 2012
Table 5-1: Ranking of Medications by Sales (2013)
Table 6-1: Number of Generics Drugs by Country (2013)
Table 7-1: Prevalence of Overweight and Obesity by Gender (%), 2013
Table 10-1: Hypermarcas – Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-2: Ache Laboratories – Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-3: Novartis – Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-4: Pfizer – Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-5: Merck Group – Revenue by Business Segments (Million US$), 2012 & 2013



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ブラジルの製薬市場展望2018]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆